FindTrial
Sign In

Efprezimod alfa

DRUG4 trials

Sponsors

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Acute Graft Versus Host DiseaseAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaCoronavirus Disease 2019 (COVID-19)Graft Versus Host DiseaseHealthy VolunteersHematopoietic Stem Cell TransplantationLeukemia

Phase 1

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
CompletedNCT02650895
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Healthy Volunteers
Start: 2014-06-02End: 2015-01-15Updated: 2023-01-12

Phase 2

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
CompletedNCT02663622
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Start: 2016-09-19End: 2021-05-18Updated: 2024-01-23

Phase 3

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
TerminatedNCT04095858
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Acute Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia +2
Start: 2021-01-05End: 2021-11-05Updated: 2023-02-08
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
CompletedNCT04317040
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Coronavirus Disease 2019 (COVID-19)
Start: 2020-04-24End: 2020-10-20Updated: 2023-02-08

Related Papers

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease
Blood2023-08-309 citations
CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.
2022-08-0146 citations
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
2022-03-1125 citations
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.
2022-01-1037 citations
Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study)
Biology of Blood and Marrow Transplantation2020-01-234 citations